Our aim was to quantify circulating B cell subsets; immature/transitional, na ïve, CD27− and CD27+ memory cells and plasmablasts, in relapsing-remitting multiple sclerosis patients treated with IFN-β. The most relevant findings were a significant increase of plasmablasts and a decrease of immature/transitional B cells, resulting in a decreased ratio between those cells in relapse RRMS, together with an increase of CD27− and CD27+IgM+ memory B cell subsets in both phases of the disease. These alterations point to an active B cell response, particularly in relapse, and the above referred ratio could constitute a good biomarker of relapse in patients that underwent I FN-β treatment. (Source: Journal of Neuroimmunology)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2DmbEjY
Πέμπτη 15 Νοεμβρίου 2018
Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.